Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001 10/585772
	Serial No.	Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Young et al.
	Filing Date	July 12, 2006
	Group	Not Yet Assigned
(37 C.F.R. § 1.98(b))	IDS Filed	July 12, 2006
	Customer No.	21559

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 98/00532	Jan. 8, 1998	WIPO			
	WO 00/47733	Aug. 17, 2000	WIPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

Examiner's Initials	Document
	Agrawal et al., "Antisense and/or Immunostimulatory Oligonuleotide Therapeutics," *Current Cancer Drug Targets* 1:197-209 (2001).
	Lee et al., "GTI-2040, an Antisense Agent Targeting the Small Subunit Component (R2) of Human Ribonucleotide Reductase, Shows Potent Antitumor Activity Against a Variety of Tumors," *Cancer Research* 63:2802-2811 (2003).
	Lepoivre et al., "Alterations of Ribonucleotide Reductase Activity Following Induction of the Nitrite-Generating Pathway in Adenocarcimoma Cells," *The Journal of Biological Chemistry* 265:14143-14149 (1990).
	Mader et al., "Transcription and Activity of 5-Fluorouracil Converting Enzymes in Fluoropyrimidine Resistance in Colon Cancer *In Vitro*," *Biochem. Pharm.* 54:1233-1242 (1997).
	Pavloff et al., "Sequence Analysis of the Large and Small Subunits of Human Ribonucleotide Reductase," J. DNA Sequencing and Mapping, 2:227-234 (1992).
	Vose et al., "Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma," *Hematology Am. Soc. Hematol. Educ. Program* 241-262 (2002).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/

EXAMINER /Dana Shin/	DATE CONSIDERED 03/18/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	